Before I start, don’t forget my deal of the day! Today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!
Get $50 when you open a TradeKing account today. » Read more: Epicept Corporation (EPCT): Victim of FDA Politics? What all Cancer Company Investors Need to Know
Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
So a lot of investors have been wondering what will happen to cancer drugs that are in the Accelerated approval process because of the recent fiasco surrounding Avastin. For those that don’t know the story, Avastin is a drug for breast cancer that has had significant setbacks. The drug was approved under the FDA’s coveted Accelerated Approval Process. » Read more: Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
This post will actually be useful for several cancer companies out there so I have also included their names in the header, sorry for the ridiculously long title.
Alright ZIOPHARM investors, I have been asked what drugs garnered approval without an SPA designation by some readers. Last year, I had put together a post about how the Oncology Advisory Committee had voted in 2009, so I decided to repost that list and then include whether or not the company had received an SPA for the trial. This list focuses on cancer drugs only, so it is directly relevant to ZIOPHARM and other oncology companies with drugs in Phase III trials. » Read more: Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
Amylin Pharmaceuticals (AMLN), Eli Lilly and Company (LLY):
Amylin and Eli Lilly caught a lucky break this morning. Roche said that they would delay development of their experimental developmental diabetes drug taspoglutide by up to 12-18 months because of blood pressure issues. The company has noted that they will have to introduce a risk mitigation plan to trials to monitor the issue. The news clears the competitive pathway for Eli Lilly’s already approved drug Byetta. » Read more: Daily Pharma Watch
Is Seliciclib the Next Wonder Cancer Cure?
Man oh man, I keep reading more and more positive news about seliciclib. Today’s news about the drug the drug being able to reverse resistance to Femara and kill breast cancer cells that had grown resistant is groundbreaking to say the least. » Read more: Seliciclib: More Positive Data
Alright Cyclacel investors, today I am going to run through a brief post about why the results of Cyclacel’s drug Seliciclib are so earth shattering that it sent the share price through the roof. » Read more: The Cyclacel Data and Its Importantance in Cancer
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter